Medicine and Dentistry
Myasthenia gravis
72%
Eculizumab
55%
Patient
49%
Fatigue
37%
Placebo
23%
Posterior Reversible Encephalopathy Syndrome
19%
Myopathy
19%
Cortical Dysplasia
19%
Status Epilepticus
19%
Quality of Life
19%
Cholinergic Receptor Antibody
16%
Inpatient
14%
Therapeutic Procedure
13%
Serum
13%
Intracranial Hypotension
13%
Epileptic Seizure
13%
Electroencephalogram
13%
Adult
13%
Activities of Daily Living
10%
Endocrine Disease
9%
Symptom
9%
Immunosuppressive Treatment
8%
Artificial Respiration
7%
Chemotherapeutic Agent
7%
Drug Therapy
7%
Drug
7%
Woman
6%
Association
6%
Surgery
6%
Pathogenesis
6%
Hemispherectomy
6%
Temporal Lobe
6%
Evaluation Study
6%
Right Hemisphere
6%
Cerebrospinal Fluid
6%
Brain Biopsy
6%
Neuroimaging
6%
Ictal
6%
Liquorrhea
6%
Adjustment
6%
Respiratory Failure
5%
Muscle
5%
Pharmacology, Toxicology and Pharmaceutical Science
Eculizumab
100%
Myasthenia gravis
80%
Duchenne Muscular Dystrophy
39%
Symptom
25%
Rituximab
20%
Posterior Reversible Encephalopathy Syndrome
19%
Drug Development
19%
Diseases
16%
Golden Retriever
15%
Muscular Dystrophy
15%
Placebo
15%
Pathogenesis
14%
Fatigue
13%
Intracranial Hypotension
13%
Dog
11%
Syndrome
9%
Cholinergic Receptor Antibody
8%
Clinical Trial
7%
Biological Marker
7%
Dystrophin
7%
Rare Disease
7%
Cholinergic Receptor
7%
Pear
6%
Liquorrhea
6%
Respiratory Failure
5%